Skip to content
Nonprofiteer
← THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Form 990 for tax year 2022

Filed by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC.

Totals

Total revenue
$45,044,474
Total expenses
$38,280,730
Contributions and grants received
$42,022,114
Grants paid
$4,589,741
Program service revenue
$2,152,800
Investment income
$670,999
Other revenue
$198,561
Total assets, end of year
$89,097,661
Total liabilities, end of year
$25,407,747
Net assets or fund balances, end of year
$63,689,914
Program services expenses (Part IX)
$32,231,243
Management and general expenses
$1,151,462
Fundraising expenses
$4,898,025
Program service expenses (Part III)
$32,231,243

Program services were 84.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $42,022,114

  • 1g · Noncash contributions included above

    $191,034

  • 2a · Program service revenue: RESEARCH & CLINICAL TRIALS

    total $2,152,800 · related or exempt $2,152,800

  • 3 · Investment income

    total $679,638 · excluded $679,638

  • 5 · Royalties

    total $192,561 · related or exempt $192,561

  • 7a · Gross sales of assets other than inventory

    securities $93,023,508

  • 7b · Less cost or other basis and sales expenses

    securities $93,032,147

  • 7c · Gain or loss

    securities -$8,639

  • 7d · Net gain or loss

    total -$8,639 · excluded -$8,639

  • 11a · Other revenue: OTHER INCOME

    total $6,000 · excluded $6,000

  • 11e · Other revenue, total

    $6,000

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $4,532,241 · program services $4,532,241

  • 3 · Grants to foreign organizations and individuals

    total $57,500 · program services $57,500

  • 5 · Compensation of officers, directors and key employees

    total $3,961,065 · program services $2,799,433 · management and general $372,096 · fundraising $789,536

  • 7 · Other salaries and wages

    total $5,211,096 · program services $3,682,879 · management and general $489,521 · fundraising $1,038,696

  • 8 · Pension plan contributions

    total $170,487 · program services $120,490 · management and general $16,015 · fundraising $33,982

  • 9 · Other employee benefits

    total $404,960 · program services $286,201 · management and general $38,041 · fundraising $80,718

  • 10 · Payroll taxes

    total $627,329 · program services $443,357 · management and general $58,930 · fundraising $125,042

  • 11a · Fees: management

    total $1,050,024 · program services $933,603 · management and general $20,547 · fundraising $95,874

  • 11b · Fees: legal

    total $116,025 · program services $101,769 · management and general $3,662 · fundraising $10,594

  • 11c · Fees: accounting

    total $60,200 · program services $52,803 · management and general $1,900 · fundraising $5,497

  • 11g · Fees: other

    total $8,270,865 · program services $7,192,987 · management and general $34,487 · fundraising $1,043,391

  • 12 · Advertising and promotion

    total $845,594 · program services $546,766 · management and general $26,688 · fundraising $272,140

  • 13 · Office expenses

    total $1,475,787 · program services $1,331,614 · management and general $4,201 · fundraising $139,972

  • 14 · Information technology

    total $1,404,775 · program services $1,232,174 · management and general $44,336 · fundraising $128,265

  • 16 · Occupancy

    total $227,995 · program services $199,982 · management and general $7,196 · fundraising $20,817

  • 17 · Travel

    total $647,770 · program services $421,737 · management and general $4,580 · fundraising $221,453

  • 19 · Conferences, conventions and meetings

    total $886,269 · program services $36,263 · fundraising $850,006

  • 22 · Depreciation, depletion and amortization

    total $951,835 · program services $900,195 · management and general $24,211 · fundraising $27,429

  • 23 · Insurance

    total $160,043 · program services $140,379 · management and general $5,051 · fundraising $14,613

  • 24a · Other expenses: CLINICAL TRIALS

    total $6,644,828 · program services $6,644,828

  • 24b · Other expenses: TISSUE BANKING

    total $574,042 · program services $574,042

  • 26 · Joint costs (an allocation of the lines above)

    total $192,371 · program services $95,308 · management and general $0 · fundraising $97,063

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $13,953,290 · end of year $5,060,628

  • 2 · Savings and temporary cash investments

    beginning of year $21,392,706 · end of year $13,092,430

  • 3 · Pledges and grants receivable

    beginning of year $5,289,425 · end of year $5,229,372

  • 4 · Accounts receivable

    beginning of year $7,335,350 · end of year $8,274,610

  • 9 · Prepaid expenses and deferred charges

    beginning of year $225,493 · end of year $896,043

  • 10a · Land, buildings and equipment: cost or other basis

    $6,732,447

  • 10b · Land, buildings and equipment: accumulated depreciation

    $3,768,321

  • 10c · Land, buildings and equipment, net

    beginning of year $1,816,801 · end of year $2,964,126

  • 11 · Investments: publicly traded securities

    beginning of year $29,648,577 · end of year $41,091,535

  • 13 · Investments: program-related

    beginning of year $5,648,228 · end of year $11,719,698

  • 15 · Other assets

    beginning of year $91,977 · end of year $769,219

  • 17 · Accounts payable and accrued expenses

    beginning of year $12,252,194 · end of year $15,173,286

  • 18 · Grants payable

    beginning of year $3,265,756 · end of year $43,261

  • 19 · Deferred revenue

    beginning of year $12,157,093 · end of year $9,131,077

  • 25 · Other liabilities

    beginning of year $492,004 · end of year $1,060,123

  • 27 · Net assets without donor restrictions

    beginning of year $45,234,580 · end of year $56,121,149

  • 28 · Net assets with donor restrictions

    beginning of year $12,000,220 · end of year $7,568,765

Mission and programs · 2022

Mission

SEE SCHEDULE O

  • THE IMMUNE SYSTEM IS A CRITICAL FACTOR IN MYELOMA PROGNOSIS AND TREATMENT BECAUSE IT CAN DETECT AND DESTROY ABNORMAL CELLS, INCLUDING CANCER CELLS. TO ADVANCE OUR UNDERSTANDING OF HOW A MYELOMA PATIENT'S IMMUNE SYSTEM CHANGES DURING THE DEVELOPMENT OF THEIR DISEASE AND HOW IT IS AFFECTED BY THERAPY, WE ARE DEVELOPING AN IMMUNE FOCUSED DATABASE, CALLED THE MMRF IMMUNE ATLAS. IT UTILIZES PATIENT SAMPLES AND CLINICAL DATA FROM OUR GROUNDBREAKING COMMPASS STUDY - ONE OF THE LARGEST MYELOMA DATASETS IN THE PUBLIC DOMAIN. THE IMMUNE ATLAS IS DESIGNED TO DESCRIBE THE MYELOMA PATIENT IMMUNE SYSTEM FROM DISEASE DEVELOPMENT, THROUGH DIAGNOSIS, AND THE TREATMENT JOURNEY. THE INFORMATION, COLLECTED FROM HUNDREDS OF PATIENTS, WILL BE COMBINED WITH THE EXISTING GENOMIC AND CLINICAL DATA FROM COMMPASS TO DEVELOP A MORE COMPREHENSIVE PICTURE OF MYELOMA DISEASE BIOLOGY. THE INSIGHTS GENERATED THROUGH IMMUNE ATLAS WILL HELP GUIDE OPTIMAL TREATMENT APPROACHES FOR MYELOMA PATIENTS IN THE FUTURE.

    Expenses $7,028,145 · Grants $1,363,694 · Revenue $2,345,361

  • THE MMRF CURECLOUD IS A FIRST-OF-ITS-KIND REGISTRY THAT COLLECTS GENOMIC AND CLINICAL INFORMATION TO INFORM BETTER TREATMENTS FOR PATIENTS. THE AGGREGATED DATA IS ALSO DESIGNED TO HELP RESEARCHERS DISCOVER NEW TARGETS FOR MYELOMA AND FORM HYPOTHESES FOR CLINICAL TRIALS.PATIENTS PARTICIPATING IN CURECLOUD CONTRIBUTE A BLOOD SAMPLE THAT IS SENT TO A CENTRAL LAB FOR DNA SEQUENCING. THIS SEQUENCING DATA IS COMBINED WITH THE PATIENT'S MEDICAL RECORDS TO PROVIDE A BETTER UNDERSTANDING OF THEIR DISEASE HISTORY. ALL PATIENT DATA STORED IN CURECLOUD IS THEN ANONYMIZED, AGGREGATED, AND WILL BE SHARED WITH RESEARCHERS AND MEDICAL PROFESSIONALS. TO DATE, MORE THAN 1,000 PATIENTS HAVE ENROLLED. IN THE FALL OF 2022, TWO PATIENT REPORTED OUTCOME (PRO) SURVEYS WERE ADMINISTERED TO CURECLOUD PARTICIPANTS IN ORDER TO TRACK PATIENT EXPERIENCES WITH MYELOMA THERAPY OVER TIME AND ACROSS TREATMENTS. THE CANCER THERAPY SATISFACTION QUESTIONNAIRE MEASURED EXPECTATIONS OF THERAPY, FEELINGS ABOUT SIDE EFFECTS, AND SATISFACTION WITH CANCER THERAPY. THE FACIT COST SURVEY MEASURED THE FINANCIAL IMPACT RELATED TO THERAPY EXPERIENCED BY MYELOMA PATIENTS. CURECLOUD WILL BE CLOSING PATIENT ENROLLMENT AT THE END OF 2023.

    Expenses $3,226,047 · Grants $3,226,047

  • THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC) IS A NETWORK OF LEADING MYELOMA TREATMENT CENTERS THAT CONDUCT EARLY-STAGE CLINICAL TRIALS TO EVALUATE NOVEL TREATMENT STRATEGIES FOR PATIENTS. THIS COLLABORATIVE RESEARCH MODEL HAS CONDUCTED CLOSE TO 100 PHASE I AND PHASE II CLINICAL TRIALS, ENROLLING OVER A THOUSAND PATIENTS TO DATE. THE MMRC CONTINUES TO SUCCESSFULLY FOSTER THE DEVELOPMENT OF NOVEL THERAPIES AND CHAMPION RIGOROUS RESEARCH AND CLINICAL TRIALS. CURRENT MMRC CLINICAL TRIALS THAT HAVE THE POTENTIAL TO MAKE SIGNIFICANT CONTRIBUTIONS FOR MYELOMA TREATMENT INCLUDE: MYDRUGTHE MMRF MYDRUG STUDY IS THE FIRST PLATFORM TRIAL IN MYELOMA. THE PURPOSE OF MYDRUG IS TO TEST TARGETED THERAPIES NOT YET APPROVED IN MYELOMA, IN COMBINATION WITH A STANDARD OF CARE ORAL TRIPLET THERAPY, IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA PATIENTS WHO DEMONSTRATE SPECIFIC GENETIC ALTERATIONS. IT IS EVALUATING TREATMENTS THAT ARE TARGETED AGAINST SPECIFIC GENOMIC ALTERATIONS WITHIN THE MYELOMA CELLS.THE SCIENTIFIC HYPOTHESIS FOR THE MYDRUG CLINICAL TRIAL CAME OUT OF OUR COMMPASS STUDY, WHICH HAS GENERATED THE LARGEST MYELOMA GENOMICS DATABASE OPENLY ACCESSIBLE TO RESEARCHERS ACROSS THE GLOBE. THE MYDRUG STUDY IS EXPECTED TO CLOSE NEW ENROLLMENTS IN 2024. ELO-IBER (RELAPSED/REFRACTORY)IBERDOMIDE (CC-220) IS A NEW AND POTENTIALLY MORE POTENT MEMBER OF A CLASS OF MEDICINES KNOWN AS IMMUNOMODULATORS (IMIDS), WHICH INCLUDES REVLIMID (LENALIDOMIDE) AND POMALYST (POMALIDOMIDE). THIS IS A PHASE 1B/2 STUDY THAT WILL HELP DETERMINE THE OPTIMAL DOSE OF IBERDOMIDE THAT CAN BE GIVEN TO PATIENTS - IN COMBINATION WITH EMPLICITI (ELOTUZUMAB) AND DEXAMETHASONE - THAT IS SAFE AND HAS THE FEWEST SIDE EFFECTS. ARCELLX (RELAPSED/REFRACTORY)CART-DDBCMA IS A CAR-T CELL THERAPY CANDIDATE THAT USES PATIENT T CELLS THAT HAVE BEEN GENETICALLY MODIFIED TO RECOGNIZE AND KILL MYELOMA CELLS. THIS NEWER VERSION OF CAR-T CELL THERAPY IS DESIGNED TO FORM A STRONGER BOND TO BCMA, A COMMON TARGET FOR MYELOMA TREATMENT, AND KILL MYELOMA CELLS MORE EFFICIENTLY THAN PREVIOUS THERAPIES. BEIGENE (RELAPSED/REFRACTORY)THIS PHASE I/II STUDY IS EVALUATING HOW SAFE AND EFFECTIVE A NEW TARGETED THERAPY (BGB-11417) IS ALONE, AND IN COMBINATION WITH KYPROLIS (CARFILZOMIB) AND DEXAMETHASONE, IN PEOPLE WITH RELAPSED OR REFRACTORY MYELOMA. BGB-11417 IS A BCL-2 INHIBITOR THAT IS POTENTIALLY EFFECTIVE IN MYELOMA PATIENTS WITH THE 11;14 CHROMOSOMAL TRANSLOCATION, WHICH ACCOUNTS FOR ABOUT 20% OF PATIENTS. SARCAR IST THIS TRIAL WILL DETERMINE THE SIDE EFFECTS AND BEST DOSE OF SARCLISA (ISATUXIMAB) WHEN GIVEN TOGETHER WITH CARFILZOMIB WITH OR WITHOUT DEXAMETHASONE AND LENALIDOMIDE IN TREATING PATIENTS WITH RELAPSED/REFRACTORY MYELOMA. IN ARM 1, IT WILL DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF SARCLISA IN COMBINATION WITH STANDARD KYPROLIS. IN ARM 2, IT WILL STUDY THE SAFETY AND EFFICACY OF ADDING SARCLISA DOSES EVERY OTHER WEEK IN COMBINATION WITH WEEKLY KYPROLIS AND DEXAMETHASONE. AFTER COMPLETION OF STUDY TREATMENT, PATIENTS ARE FOLLOWED UP AT 30 AND 60 DAYS AND THEN EVERY 3 MONTHS FOR UP TO 3 YEARS.

    Expenses $2,713,588

  • IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE FOR EACH AND EVERY PATIENT.

    Expenses $19,263,463

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Kathy Giusti

    FOUNDER & DIRECTOR

    Total calculated
    $736,867
    From this org
    $736,667
    From related orgs
    $0
    Other
    $200
    Hours/week
    30

    Schedule J breakdown matched by us

    Base
    $0
    Bonus
    $120,000
    Other
    $616,667
    Deferred
    $200
    Nontaxable benefits
    $0
    Filer's total
    $736,867
  • Thomas Conheeney

    CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Gerald McDougall

    VICE CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Kenneth Anderson MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Karen Andrews

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Rodney Gilmore

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • David Lucchino

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Lori Tauber-Marcus

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Hugh Martin

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Susan Marvin

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • William McKiernan

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Michael Mortimer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • David Parkinson MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Marie Pinizzotto MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Adrian Rosenkranz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Steve Shak MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Kimberly White

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Michael Andreini

    PRESIDENT & CEO

    Total calculated
    $517,478
    From this org
    $494,070
    From related orgs
    $0
    Other
    $23,408
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $325,049
    Bonus
    $135,000
    Other
    $34,021
    Deferred
    $15,050
    Nontaxable benefits
    $8,358
    Filer's total
    $517,478
  • Robert Miani

    TREASURER & CFO

    Total calculated
    $384,663
    From this org
    $359,867
    From related orgs
    $0
    Other
    $24,796
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $249,179
    Bonus
    $91,600
    Other
    $19,088
    Deferred
    $16,032
    Nontaxable benefits
    $8,764
    Filer's total
    $384,663
  • Karen Dietz

    SECRETARY CAO & GENERAL COUNSEL

    Total calculated
    $294,161
    From this org
    $271,181
    From related orgs
    $0
    Other
    $22,980
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $202,155
    Bonus
    $48,000
    Other
    $21,026
    Deferred
    $12,994
    Nontaxable benefits
    $9,986
    Filer's total
    $294,161
  • Anne Quinn Young

    CHIEF MISSION OFFICER

    Total calculated
    $359,860
    From this org
    $341,011
    From related orgs
    $0
    Other
    $18,849
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $251,766
    Bonus
    $64,000
    Other
    $25,245
    Deferred
    $12,235
    Nontaxable benefits
    $6,614
    Filer's total
    $359,860
  • Peter Kosa

    MIF MANAGING DIRECTOR

    Total calculated
    $463,255
    From this org
    $429,658
    From related orgs
    $0
    Other
    $33,597
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $274,116
    Bonus
    $115,000
    Other
    $40,542
    Deferred
    $12,400
    Nontaxable benefits
    $21,197
    Filer's total
    $463,255
  • George Mulligan

    CHIEF SCIENTIFIC OFFICER

    Total calculated
    $259,376
    From this org
    $233,560
    From related orgs
    $0
    Other
    $25,816
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $222,208
    Bonus
    $0
    Other
    $11,352
    Deferred
    $9,546
    Nontaxable benefits
    $16,270
    Filer's total
    $259,376
  • Mindy Flinn

    VP OF DEVELOPMENT

    Total calculated
    $254,746
    From this org
    $227,153
    From related orgs
    $0
    Other
    $27,593
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $191,010
    Bonus
    $22,000
    Other
    $14,143
    Deferred
    $9,400
    Nontaxable benefits
    $18,193
    Filer's total
    $254,746
  • Christopher Williams

    VP OF ALLIANCE MANAGEMENT

    Total calculated
    $257,953
    From this org
    $229,055
    From related orgs
    $0
    Other
    $28,898
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $196,652
    Bonus
    $22,000
    Other
    $10,403
    Deferred
    $9,480
    Nontaxable benefits
    $19,418
    Filer's total
    $257,953
  • Hearn Cho

    CHIEF MEDICAL OFFICER

    Total calculated
    $217,186
    From this org
    $208,833
    From related orgs
    $0
    Other
    $8,353
    Hours/week
    32

    Schedule J breakdown matched by us

    Base
    $154,682
    Bonus
    $38,000
    Other
    $16,151
    Deferred
    $8,353
    Nontaxable benefits
    $0
    Filer's total
    $217,186
  • Eva M Lepisto

    VP OF INFORMATICS

    Total calculated
    $215,518
    From this org
    $204,912
    From related orgs
    $0
    Other
    $10,606
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $184,438
    Bonus
    $10,000
    Other
    $10,474
    Deferred
    $9,620
    Nontaxable benefits
    $986
    Filer's total
    $215,518
  • Greg Rubenstein

    VP OF MARKETING

    Total calculated
    $241,996
    From this org
    $212,086
    From related orgs
    $0
    Other
    $29,910
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $176,261
    Bonus
    $21,000
    Other
    $14,825
    Deferred
    $8,807
    Nontaxable benefits
    $21,103
    Filer's total
    $241,996
  • Charles Volpe

    DIRECTOR, PR & COMMUNCIATIONS

    Total calculated
    $196,055
    From this org
    $173,921
    From related orgs
    $0
    Other
    $22,134
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $148,543
    Bonus
    $14,000
    Other
    $11,378
    Deferred
    $0
    Nontaxable benefits
    $22,134
    Filer's total
    $196,055
  • Todd Brooks

    SR DIRECTOR, DEVELOPMENT

    Total calculated
    $187,539
    From this org
    $179,543
    From related orgs
    $0
    Other
    $7,996
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $155,996
    Bonus
    $13,000
    Other
    $10,547
    Deferred
    $7,176
    Nontaxable benefits
    $820
    Filer's total
    $187,539
  • Heather Steiger

    DIRECTOR, DIGITAL MARKETING

    Total calculated
    $186,021
    From this org
    $169,691
    From related orgs
    $0
    Other
    $16,330
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $147,199
    Bonus
    $13,000
    Other
    $9,492
    Deferred
    $0
    Nontaxable benefits
    $16,330
    Filer's total
    $186,021
  • Joanne Puglia

    SR DIRECTOR FINANCE, CONTROLLER

    Total calculated
    $195,996
    From this org
    $185,860
    From related orgs
    $0
    Other
    $10,136
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $151,600
    Bonus
    $17,600
    Other
    $16,660
    Deferred
    $7,437
    Nontaxable benefits
    $2,699
    Filer's total
    $195,996

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 4a · Severance or change-of-control payment
  • 7 · Other non-fixed payments

Answered no

  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 4A
KATHY GIUSTI, FOUNDER AND FORMER CHIEF MISSION OFFICER, RECEIVED A $250,000 SEVERANCE PAYMENT IN HER 2022 W-2.
PART I, LINE 7
INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2022, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2022 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$2,057,500

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING — $30,000
NORTH AMERICA 0 0 GRANTMAKING — $27,500
MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS — $2,000,000

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
EUROPE (INCLUDING ICELAND & GREENLAND) $30,000 WIRE $0 — —
NORTH AMERICA $27,500 WIRE $0 — —
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
2
Other grantees (Part II line 3)
0
Transferred property to a foreign corporation during the year (line 1)
Yes
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
Yes
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • MYELOMA INVESTMENT FUND LLC

    VENTURE PHILANTHROPY FUND · DE · income $2,627,469 · assets $19,892,015

    Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

  • MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC

    FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH · CT · income $6,154,809 · assets $2,589,106

    Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Provenance

Return type
form_990
Tax year
2022
Filed
30 October 2023
IRS schema version
2022v5.0
Source object
202313039349302071

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.